Prithvi_Mruthyunjaya Profile
Prithvi_Mruthyunjaya

@eyeamprithvi

Followers
373
Following
51
Media
1
Statuses
28

Associate Professor of Ophthalmology, Director of ocular oncology, director of vitreoretinal surgery fellowship at Stanford University. my tweets are personal

Palo Alto, CA
Joined April 2014
Don't wanna be here? Send us removal request.
@3Y3MD
Ian Han, MD
5 years
Academics is not about finding your “niche” but developing expertise and sharing skills in collaboration with colleagues. Find common purpose. Develop shared vision. Discuss differences over ☕️. Listen and learn. Work together. Make the 🌎 better and brighter. #btcywt👁
0
3
23
@TheLens_oph
The Lens: Ophthalmology Research Newsletter
5 years
Check out this interesting paper in @AAOjournal written by @RaviParikhMD, @eyeamprithvi, @DrKNwan, and others about changing OOP costs for ophthalmic drugs! #Ophthalmology #MedTwitter #ACA https://t.co/8Cn1sNOrJp 1/2
1
1
5
@eyeamprithvi
Prithvi_Mruthyunjaya
5 years
AddThis | Home https://t.co/qbB3MKiATs Our article on total US expenditures on Ophthalmic care shows overall expenditure is up, but out of pocket is down. We outline factors including rebates, policies, and pricey eye drops. Kudos @RaviParikhMD and teams from NYU and Yale
0
0
13
@eyeamprithvi
Prithvi_Mruthyunjaya
6 years
Great team of students and colleagues from #stanfordretina addressing #diparities in #Cancer patients, specifically in #ocularmelanoma.
0
0
12
@eyeamprithvi
Prithvi_Mruthyunjaya
6 years
Great to work with the talented @RaviParikhMD on this study.
@RaviParikhMD
Ravi Parikh, MD MPH
6 years
Thanks to my team and collaborators from @stanford, @HopkinsMedicine, @yale, and @MassEyeAndEar Clinical trial evidence and reimbursement appear to be shifting practice patterns for #diabetes in the eye from laser surgery (PRP) to surgical delivery of antivegf (eye injections).
0
0
5
@AAOjournal
Ophthalmology
6 years
PRP rates for proliferative #diabeticretinopathy declined significantly & anti-VEGF rates significantly increased after publication of Protocol S. @ameeazad @RaviParikhMD @eyeamprithvi https://t.co/HLYxtsUqhj
0
8
12
@eyeamprithvi
Prithvi_Mruthyunjaya
6 years
Excellent work by our #stanfordretina team identifying ongoing disparities in cancer patients. @ByersEye @dmoshfeghi @NRajeshuni @TalhahZubair @cassieludwig @StanfordMed
@JAMAOphth
JAMA Ophthalmology
6 years
Race, ethnicity, & socioeconomic status are assoc'd w differences in enucleation rates for pts w uveal #melanoma even controlling for stage at presentation https://t.co/1buTPCPUUH @NRajeshuni @talhahzubair @cassieludwig @dmoshfeghi @eyeamprithvi #medtwitter #meded #somedocs
1
3
6
@JWHarbourMD
J William Harbour MD
6 years
Read my latest #research on uveal melanoma single cell analysis, published with @SpringerNature in @NatureComms. Read and share here: https://t.co/2dQEHX6aQW. @BascomPalmerEye @SylvesterCancer #cancer #melanoma #uvealmelanoma #ocularoncology
0
17
38
@surgeonretina
Rajesh Rao, MD
6 years
From @AAOjournal: #PrivateEquity in #Ophthalmology & #Optometry: Analysis of Acquisitions from 2012 to 2019 in USA. 228 practices associated w/ 1,466 locations & 2,146 #ophthalmologists or #optometrists were acquired by 29 private equity-backed companies. https://t.co/LU1eq9tFFK
0
5
3
@JWHarbourMD
J William Harbour MD
6 years
@UMCURE2020 This is the 10 year anniversary of our discovery that BAP1 loss is the single most important predictor of uveal melanoma metastasis ( https://t.co/HMQHrGxSOG). Our French colleagues are the latest to confirm this and to show that chr 3 loss is only relevant if it includes BAP1.
Tweet card summary image
pubmed.ncbi.nlm.nih.gov
Metastasis is a defining feature of malignant tumors and is the most common cause of cancer-related death, yet the genetics of metastasis are poorly understood. We used exome capture coupled with...
0
10
9
@eyeamprithvi
Prithvi_Mruthyunjaya
6 years
Nice study, as always, @drrishisingh
@drrishisingh
Dr. Rishi P. Singh MD
6 years
Our study was just published on long term outcomes of patients treated with Eplerenone for the treatment of chronic central serous chorioretinopathy. ⁦@CleClinicNews⁩ ⁦@CleClinicMD#coleeyeinstitute
0
0
2
@eyeamprithvi
Prithvi_Mruthyunjaya
6 years
Excellent work by the @ByersEye team of @dmoshfeghi @cassieludwig @dvail
@surgeonretina
Rajesh Rao, MD
6 years
Authors @ByersEye @StanfordMed report large, multi-center retrospective cohort study of commercially insured patients: 227,325 patients with interstitial cystitis (for which pentosan polysulfate sodium may be prescribed) who were continuously enrolled in the MarketScan database.
0
0
4
@dvail
dgv
6 years
In this paper we explore the ways that management of an ophthalmic emergency varies by the day of the week that it’s diagnosed. With @carolynkpan @eyeamprithvi and Suzann Pershing
@JAMAOphth
JAMA Ophthalmology
6 years
Management of rhegmatogenous retinal detachment repair associated with the day of the week they are diagnosed and repaired
0
1
5
@JAMAOphth
JAMA Ophthalmology
6 years
­­­Genetic analysis suggests that unilateral multifocal uveal melanoma may represent intraocular metastasis with increased risk of systemic metastasis
0
6
8
@eyeamprithvi
Prithvi_Mruthyunjaya
6 years
Association of Rhegmatogenous Retinal Detachment and Outcomes With the Day of the Week That Patients Undergo a Repair or Receive a Diagnosis | Ophthalmology | JAMA Ophthalmology | JAMA Network
Tweet card summary image
jamanetwork.com
This cohort study assesses the association between modality of rhegmatogenous retinal detachment repair and the day of the week that patients receive a diagnosis or undergo retinal detachment repair.
0
0
4
@dukeleuk
Arati Rao
6 years
Excited to present ZUMA2 data of KTE-X19 in R/R MCL at #ASH19 which has also been selected for “Best Of ASH” -that too with preliminary data of 28 patients. Eager to share the full data set with the oncology community at the oral presentation! https://t.co/XRRDxqshDs
0
2
5
@SCIDirector
Steven Artandi, MD, PhD
7 years
After 9 mos of #retinoblastoma Tx, 3 yr old Cru is stabilized and back home, racing trucks and riding tricycles. SCI member Prithvi Mruthyunjaya states: "We look forward to watching Cru grow up to become a healthy young man!” https://t.co/jwzQhDv667 @eyeamprithvi @StanfordCancer
1
3
9
@eyeamprithvi
Prithvi_Mruthyunjaya
7 years
Ocular melanoma is a serious cancer that starts in the eye —work with us to fight and cure. Come walk shoulder to shoulder with survivors and their families.
Tweet card summary image
facebook.com
Register now at lookinforacure.org to get the early bird price of $25 for the 2nd annual “Lookin’ for a Cure Ocular Melanoma Benefit 5K Fun Run and Walk” on May 19 hosted by the Byers Eye Institute...
0
1
3
@eyeamprithvi
Prithvi_Mruthyunjaya
7 years
20 days until #ICOO2019 !
0
0
0